---
title: "炸裂！MD Anderson顶级团队重磅发声，彻底颠覆肿瘤治疗底层逻辑，精准医疗迎来“降维打击”！"
date: 2026-01-14T14:31:35Z
draft: ["false"]
tags: [
  "fetched",
  "CNS文献精读会"
]
categories: ["Acdemic"]
---
炸裂！MD Anderson顶级团队重磅发声，彻底颠覆肿瘤治疗底层逻辑，精准医疗迎来“降维打击”！ by CNS文献精读会
------
<div><section data-pm-slice="0 0 []"><section><section><section><section><section><p><strong><span leaf="">点击蓝字 关注我们</span></strong></p></section><section><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section><section><section><section><section><p><span leaf=""><br></span></p></section></section></section><section><section><section><p><span leaf=""><br></span></p></section></section></section><section><section><section><p><span leaf=""><br></span></p></section></section></section></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011064" data-ratio="1.7065463" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXTryO8icoqPkscdGYTv1Bm5bgESwOU1ibiclzpiccF7Gbpo7vXyPBR56ia1w/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="443" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXTryO8icoqPkscdGYTv1Bm5bgESwOU1ibiclzpiccF7Gbpo7vXyPBR56ia1w/640?wx_fmt=png&amp;from=appmsg"></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011067" data-ratio="1.074" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXb0U3AE4DwLTkNwDICcQ7qukicYjtMwghaCuIl8wPl4PXTIyMMtlbOYA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXb0U3AE4DwLTkNwDICcQ7qukicYjtMwghaCuIl8wPl4PXTIyMMtlbOYA/640?wx_fmt=png&amp;from=appmsg"></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011066" data-ratio="0.8" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX3sNx4AaQsibrzjOyiaLn9tM9lchvY3ib2OofEwqolz7zICOl8VKev1AHQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX3sNx4AaQsibrzjOyiaLn9tM9lchvY3ib2OofEwqolz7zICOl8VKev1AHQ/640?wx_fmt=png&amp;from=appmsg"></section></section></section></section></section></section><section><section><section><section><section><section><section><section data-cacheurl="" data-remoteid=""><section><section><p><strong><span leaf="">01</span></strong></p></section></section></section></section></section><section><section><section><section><section><section><p><span leaf=""><br></span></p></section></section></section><section><section><section><p><span leaf=""><br></span></p></section></section></section><section><section><section><p><span leaf=""><br></span></p></section></section></section></section></section></section><section><section><section><p><span leaf="">长期主义</span></p></section></section><section><section><p><strong><span leaf="">文献信息</span></strong></p></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011065" data-ratio="1.7065463" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXTryO8icoqPkscdGYTv1Bm5bgESwOU1ibiclzpiccF7Gbpo7vXyPBR56ia1w/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="443" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXTryO8icoqPkscdGYTv1Bm5bgESwOU1ibiclzpiccF7Gbpo7vXyPBR56ia1w/640?wx_fmt=png&amp;from=appmsg"></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011068" data-ratio="1.074" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXb0U3AE4DwLTkNwDICcQ7qukicYjtMwghaCuIl8wPl4PXTIyMMtlbOYA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXb0U3AE4DwLTkNwDICcQ7qukicYjtMwghaCuIl8wPl4PXTIyMMtlbOYA/640?wx_fmt=png&amp;from=appmsg"></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011070" data-ratio="0.8" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX3sNx4AaQsibrzjOyiaLn9tM9lchvY3ib2OofEwqolz7zICOl8VKev1AHQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX3sNx4AaQsibrzjOyiaLn9tM9lchvY3ib2OofEwqolz7zICOl8VKev1AHQ/640?wx_fmt=png&amp;from=appmsg"></section></section></section></section></section></section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011087" data-ratio="0.5389930898321816" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXuxPACKLCNUh03P2MgNBcvO1dFsth0Jj6dYjouQic1GJg0XegmVkwIEQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="2026" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXuxPACKLCNUh03P2MgNBcvO1dFsth0Jj6dYjouQic1GJg0XegmVkwIEQ/640?wx_fmt=png&amp;from=appmsg"></section><p><strong><span leaf="">题目：</span></strong><strong><span leaf="">Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program</span></strong></p><p><strong><span leaf="">单位：</span></strong><strong><span leaf="">Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA</span></strong></p><p><strong><span leaf="">作者：</span></strong><strong><span leaf="">Scott Kopetz</span></strong></p><p><strong><span leaf="">杂志：Cancer Cell</span></strong></p><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011085" data-ratio="0.5315581854043393" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXcLYgWF8F7dicBoc59onbuFsDZO8Pzl3DTRHYlQtciaaiaSF53ka28BQgg/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="2028" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXcLYgWF8F7dicBoc59onbuFsDZO8Pzl3DTRHYlQtciaaiaSF53ka28BQgg/640?wx_fmt=png&amp;from=appmsg"></section><p><span leaf=""><span textstyle="">推荐阅读理由：</span></span></p><p data-pm-slice="0 0 []"><span leaf="">想象一下，临床上有两位医生面对同一个晚期结直肠癌（mCRC）患者：</span></p><p><strong><span leaf="">医生 A（也就是目前99%的我们）：</span></strong><span leaf=""> 按部就班地用上一线药，然后“等”</span><strong><span leaf="">。等什么？<span textstyle="">等患者复查CT，等肿瘤变大，等耐药出现。说白了，我们是在被肿瘤牵着鼻子走，永远比癌细胞</span></span></strong><span leaf="">慢一步。结果呢？患者5年生存率仅有惨淡的1%。</span></p><p><strong><span leaf="">医生 B（ASCEND-CRC计划打造的未来医生）：</span></strong><span leaf=""> 在治疗第3周，影像学还看不出任何变化时，他已经通过血液里的“Delta生物标志物”</span><strong><span leaf="">预判</span></strong><span leaf="">了治疗会失败。他没有傻傻地等到耐药长出来，而是直接换药，在癌细胞适应环境之前，以此为信号进行“半路拦截”。</span></p><p><strong><span leaf="">这就是“反应性治疗”与“进化拦截”的天壤之别。</span></strong></p><p><span leaf="">当你还在纠结基线基因检测该用哪个Panel时，</span><strong><span leaf="">MD Anderson</span></strong><span leaf=""> 联合 </span><strong><span leaf="">ARPA-H</span></strong><span leaf=""> 已经在 </span><em><span leaf="">Cancer Cell</span></em><span leaf=""> 上发表了这项堪称“科幻”的 </span><strong><span leaf="">ASCEND-CRC 计划</span></strong><span leaf="">。他们彻底抛弃了静态的治疗逻辑，提出了一套基于“实时进化”的全新打法。</span></p><p><span leaf="">这不仅仅是一个临床试验，这是对过去几十年肿瘤治疗模式的一次</span><strong><span leaf="">降维打击</span></strong><span leaf="">。如果不读懂这篇文献，你的临床思维可能真的要过时了。</span></p></section></section></section><section><section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011073" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXdfBCuQm9t5kPEcLh7Uld0nghHC69W1eAdXxEY6CKjUN9QtwibLIxNEw/640?wx_fmt=gif&amp;from=appmsg" data-type="gif" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXdfBCuQm9t5kPEcLh7Uld0nghHC69W1eAdXxEY6CKjUN9QtwibLIxNEw/640?wx_fmt=gif&amp;from=appmsg"></section></section></section></section></section><section><section><section><section><section><section data-cacheurl="" data-remoteid=""><section><section><p><strong><span leaf="">02</span></strong></p></section></section></section></section></section><section><section><section><section><section><section><p><span leaf=""><br></span></p></section></section></section><section><section><section><p><span leaf=""><br></span></p></section></section></section><section><section><section><p><span leaf=""><br></span></p></section></section></section></section></section></section><section><section><section><p><span leaf="">长期主义</span></p></section></section><section><section><p><strong><span leaf="">In Brief</span></strong></p></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011072" data-ratio="1.7065463" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXTryO8icoqPkscdGYTv1Bm5bgESwOU1ibiclzpiccF7Gbpo7vXyPBR56ia1w/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="443" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXTryO8icoqPkscdGYTv1Bm5bgESwOU1ibiclzpiccF7Gbpo7vXyPBR56ia1w/640?wx_fmt=png&amp;from=appmsg"></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011071" data-ratio="1.074" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXb0U3AE4DwLTkNwDICcQ7qukicYjtMwghaCuIl8wPl4PXTIyMMtlbOYA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXb0U3AE4DwLTkNwDICcQ7qukicYjtMwghaCuIl8wPl4PXTIyMMtlbOYA/640?wx_fmt=png&amp;from=appmsg"></section></section></section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011069" data-ratio="0.8" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX3sNx4AaQsibrzjOyiaLn9tM9lchvY3ib2OofEwqolz7zICOl8VKev1AHQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX3sNx4AaQsibrzjOyiaLn9tM9lchvY3ib2OofEwqolz7zICOl8VKev1AHQ/640?wx_fmt=png&amp;from=appmsg"></section></section></section></section></section></section><section><section><section data-tool="mdnice编辑器" data-website="https://wechat.jeffjade.com/" data-pm-slice="0 0 []"><h3 data-tool="mdnice编辑器"><span></span><span><span leaf="">1. 研究背景</span></span></h3><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011088" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXdlSLoaAb3f1ibtDVL1bNBqTW2EE9A3xMFVaxr4yAg4odrN0kCfaqWOg/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXdlSLoaAb3f1ibtDVL1bNBqTW2EE9A3xMFVaxr4yAg4odrN0kCfaqWOg/640?wx_fmt=png&amp;from=appmsg"></section><h3 data-tool="mdnice编辑器"><span></span></h3><ul><li><section><strong><span leaf="">临床困境：</span></strong><span leaf=""> 转移性结直肠癌 (mCRC) 患者预后较差（5年生存率仅1%），且目前的治疗模式是“线性的”和“反应性的”。只有在影像学确认进展后才更换治疗，这使得治疗总是滞后于肿瘤的进化。</span></section></li><li><section><strong><span leaf="">生物学矛盾：</span></strong><span leaf=""> 肿瘤在治疗压力下迅速演变（如通过非遗传性的损伤修复程序进入耐药持久状态），而治疗策略却相对静态。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011090" data-ratio="0.5375494071146245" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXYOFSo48YAVzh4r8OeYndEDJm51468ibuwFdH6VBkhtbZQ1O1Fic0FQsw/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="2024" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXYOFSo48YAVzh4r8OeYndEDJm51468ibuwFdH6VBkhtbZQ1O1Fic0FQsw/640?wx_fmt=png&amp;from=appmsg"></section></li><li><section><strong><span leaf="">ADAPT 计划：</span></strong><span leaf=""> ARPA-H 启动 ADAPT 计划，旨在通过实时监测和拦截肿瘤进化来改变这一现状，ASCEND-CRC 是其中的结直肠癌项目。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011092" data-ratio="0.5218253968253969" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXEyxJxibM4ufgia6SCQkJbnQHibicmRicOsvxz30OicprQyia3tUkTGJbIs7sQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="2016" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXEyxJxibM4ufgia6SCQkJbnQHibicmRicOsvxz30OicprQyia3tUkTGJbIs7sQ/640?wx_fmt=png&amp;from=appmsg"></section></li></ul><h3 data-tool="mdnice编辑器"><span></span><span><span leaf="">2. 关键科学问题</span></span><span></span></h3><ul><li><section><strong><span leaf="">核心问题：</span></strong><span leaf=""> 能否通过纵向的多组学分析（特别是治疗开始后早期的变化），识别出通用的“Delta 生物标志物”，从而在耐药性完全确立之前就进行干预？</span></section></li><li><section><strong><span leaf="">具体假设：</span></strong></section></li></ul><ol><li><section><span leaf="">治疗早期的适应性反应（Adaptive Response，如第3周）能比基线特征更准确地预测治疗失败。</span></section></li><li><section><span leaf="">根据实时进化轨迹调整治疗（例如在影像学进展前切换方案，或针对新出现的靶点如 YAP/RAS 突变），能显著改善 PFS。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011093" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXFGTt3SkXiak2NVgWG56Aw7tj607Kic06J9uHvL4wZGLJicF7U0Hb1O2Ww/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXFGTt3SkXiak2NVgWG56Aw7tj607Kic06J9uHvL4wZGLJicF7U0Hb1O2Ww/640?wx_fmt=png&amp;from=appmsg"></section></li></ol><h3 data-tool="mdnice编辑器"><span></span><span><span leaf="">3. 方案架构与预期逻辑</span></span><span></span></h3><p data-tool="mdnice编辑器"><strong><span leaf="">逻辑关系 (1)：【早期适应性状态】如何预测【治疗反应/耐药性】</span></strong></p><ul><li><section><strong><span leaf="">实验结果/证据：</span></strong><span leaf=""> ASCEND-CRC </span><strong><span leaf="">Phase 1 (观察性研究)</span></strong><span leaf=""> 将在基线和治疗第 3 周采集配对的组织和血液样本。研究指出，早期的耐药通常不是由新的突变驱动，而是由保守的“损伤修复程序”驱动，这些程序是通用的应激反应。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011097" data-ratio="0.5191532258064516" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXJ8EcLfqCwrBcxMb7SJVgQvrEUibVprAhnxNiaTkljoouWErY8G1ib3Cug/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1984" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXJ8EcLfqCwrBcxMb7SJVgQvrEUibVprAhnxNiaTkljoouWErY8G1ib3Cug/640?wx_fmt=png&amp;from=appmsg"></section></li><li><section><strong><span leaf="">预期指标：</span></strong><span leaf=""> 研究旨在确立一个通用的“Delta Biomarker”，即通过比较第 3 周与基线的变化，无论治疗手段如何，都能预测后续的临床反应。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011094" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX1cVk22s3m2m9zxlaIRnIxw6vTeELufG5pcic7jVsG2WIZNhQArtft9g/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX1cVk22s3m2m9zxlaIRnIxw6vTeELufG5pcic7jVsG2WIZNhQArtft9g/640?wx_fmt=png&amp;from=appmsg"></section></li></ul><p data-tool="mdnice编辑器"><strong><span leaf="">逻辑关系 (2)：【动态调整治疗策略】如何影响【无进展生存期 (PFS)】</span></strong></p><ul><li><section><strong><span leaf="">实验结果/证据：</span></strong><span leaf=""> ASCEND-CRC </span><strong><span leaf="">Phase 2 (进化试验)</span></strong><span leaf=""> 设计“优化 SOC 亚组”。如果在第 3 周检测到 Delta Biomarker 显示反应不佳（低获益概率），患者将立即从一线选择（如 FOLFOX+Cetuximab）切换到二线选择（如 FOLFIRI+Bevacizumab），而不是等待影像学进展。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011099" data-ratio="0.5291709314227226" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXDvKzjJjrfNT4hqaxtQTVIZBPaZl0Jk1N4hlJUZMnjspBJCStQ0MIgg/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1954" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXDvKzjJjrfNT4hqaxtQTVIZBPaZl0Jk1N4hlJUZMnjspBJCStQ0MIgg/640?wx_fmt=png&amp;from=appmsg"></section></li><li><section><strong><span leaf="">统计目标：</span></strong><span leaf=""> 目标入组 300 例，旨在检测中位 PFS 提高&gt;50的效应量。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011095" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXocibDLYPEZmSHjdfSkqCE8C4dOiceM3sLW5q3BDibQNMjW2uNqZl9WkQg/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXocibDLYPEZmSHjdfSkqCE8C4dOiceM3sLW5q3BDibQNMjW2uNqZl9WkQg/640?wx_fmt=png&amp;from=appmsg"></section></li></ul><p data-tool="mdnice编辑器"><strong><span leaf="">逻辑关系 (3)：【特异性进化机制】如何关联【模块化靶向治疗】</span></strong></p><ul><li><section><strong><span leaf="">实验结果/证据：</span></strong><span leaf=""> 对于产生可靶向耐药机制（如继发性 RAS 突变、YAP 激活、ecDNA 扩增）的患者，将进入模块化亚组试验。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011100" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX4qaSPqg9KPiaYaHJN3lQScq6sXIe3AwnPpjzxTmgNFNuZhibibibxYqprg/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX4qaSPqg9KPiaYaHJN3lQScq6sXIe3AwnPpjzxTmgNFNuZhibibibxYqprg/640?wx_fmt=png&amp;from=appmsg"></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011101" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXt1bzvEj9LNHnpVwkqOFCtm3IOzobjdGc6YcmahUichN4l5mhaDVNO7g/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXt1bzvEj9LNHnpVwkqOFCtm3IOzobjdGc6YcmahUichN4l5mhaDVNO7g/640?wx_fmt=png&amp;from=appmsg"></section></li><li><section><strong><span leaf="">设计亮点：</span></strong><span leaf=""> 采用贝叶斯自适应设计，表现不佳的模块会被停用，新模块可随时加入（迭代式），且利用 Phase 1 的数据生成“合成对照组”以减少对照组样本量需求。</span></section></li></ul><h3 data-tool="mdnice编辑器"><span></span><span><span leaf="">4. 创新点</span></span><span></span></h3><ol><li><section><strong><span leaf="">概念创新：</span></strong><span leaf=""> 从依赖“静态基线”标志物转变为依赖“动态变化”标志物（第 3 周 vs 基线）。重点关注早期的非遗传性适应和损伤修复状态。</span></section></li><li><section><strong><span leaf="">技术整合（多组学）：</span></strong><span leaf=""> 明确纳入</span><strong><span leaf="">空间转录组学</span></strong><span leaf="">和多重免疫荧光 (mIF)，以解析微环境和免疫决定因素，这是常规临床试验极少涉及的深度。此外还整合了 cfDNA 甲基化和微生物组。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011106" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX6xfK6Q1lGmRd9nSia9yQ6DtanrH5zesqqNLIQNkxbW26T6de1TtzHUQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX6xfK6Q1lGmRd9nSia9yQ6DtanrH5zesqqNLIQNkxbW26T6de1TtzHUQ/640?wx_fmt=png&amp;from=appmsg"></section></li><li><section><strong><span leaf="">试验设计（合成对照）：</span></strong><span leaf=""> 利用 Phase 1 的详细数据作为 Phase 2 的“合成对照”，通过倾向性评分匹配（Propensity Score Matching），让更多患者能分配到实验组（3:1 分配），提高了试验效率和患者获益机会。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011107" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX0H2XwyvecCVZhC37m1vtRgS7fGXYIibSUkPZPUAhiaZ3OgdsJjwUI3Tw/640?wx_fmt=png&amp;from=appmsg" data-type="png" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALX0H2XwyvecCVZhC37m1vtRgS7fGXYIibSUkPZPUAhiaZ3OgdsJjwUI3Tw/640?wx_fmt=png&amp;from=appmsg"></section></li></ol><h3 data-tool="mdnice编辑器"><span></span><span><span leaf="">5. 不足与挑战</span></span><span></span></h3><ol><li><section><strong><span leaf="">数据挑战：</span></strong><span leaf=""> 如何实时（Real-time）整合如此庞大的多组学数据（基因组、转录组、空间、临床数据）并在 2 周内反馈给临床医生以指导决策，是巨大的技术瓶颈。</span></section></li><li><section><strong><span leaf="">监管挑战：</span></strong><span leaf=""> 这种模块化、贝叶斯自适应、且不断迭代（新药加入、旧药淘汰）的试验设计，与FDA传统的监管框架不兼容，需要建立新的监管范式。</span></section></li><li><section><strong><span leaf="">患者依从性：</span></strong><span leaf=""> 这种高密度的纵向活检（每线治疗都要前后活检）对患者的利他精神和身体状况是巨大考验。</span></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011103" data-ratio="0.5181818181818182" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXiaMgB88gzjAdSJ2k5HkYyWf7waCNicicy5dm118WtOia8o7XTlpda1ZJxA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1980" type="block" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXiaMgB88gzjAdSJ2k5HkYyWf7waCNicicy5dm118WtOia8o7XTlpda1ZJxA/640?wx_fmt=png&amp;from=appmsg"></section></li></ol></section><p><span leaf=""><br></span></p></section></section><section><section><section><p><strong><span leaf="">往期</span></strong></p></section><section><p><span leaf="">RECOMMEND</span></p></section><section><p><strong><span leaf="">推荐</span></strong></p></section></section><section><section><p><span leaf="">·<a target="_blank" href="https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&amp;mid=2247488921&amp;idx=1&amp;sn=a46964728caa65276f04e03dbfde037b&amp;scene=21#wechat_redirect" textvalue="精通文献汇报：DeepSeek结合BRTR指令法的深度解读与应用" data-itemshowtype="0" linktype="text" data-linktype="2">精通文献汇报：DeepSeek结合BRTR指令法的深度解读与应用</a></span></p></section><section><section><svg viewbox="0 0 1 1"></svg></section></section><section><p><span leaf="">·<a target="_blank" href="https://mp.weixin.qq.com/s?__biz=MzkzMzY5NDk3NA==&amp;mid=2247494711&amp;idx=1&amp;sn=9492e52e4365295e45cc623884b507ad&amp;scene=21#wechat_redirect" textvalue="太强了！2026广医大&amp;交大团队首发Cell，颠覆铁死亡领域认知，取得肿瘤免疫史上最大突破，堪称奇迹！" data-itemshowtype="0" linktype="text" data-linktype="2">太强了！2026广医大&amp;交大团队首发Cell，颠覆铁死亡领域认知，取得肿瘤免疫史上最大突破，堪称奇迹！</a></span></p></section><section><section><svg viewbox="0 0 1 1"></svg></section></section><section><section><svg viewbox="0 0 1 1"></svg></section></section><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011079" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXcUZDmaaex9ia8OnxzDFiaP4icK9XqA4AkMXgAEncdoWP8MBhYfAkCIRDQ/640?wx_fmt=gif&amp;from=appmsg" data-type="gif" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXcUZDmaaex9ia8OnxzDFiaP4icK9XqA4AkMXgAEncdoWP8MBhYfAkCIRDQ/640?wx_fmt=gif&amp;from=appmsg"></section></section><section><section><p><strong><span leaf="">点个赞吧</span></strong></p></section></section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011078" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXmIH3xGbloEopsHBwr4D3Ks7Qn46CSnBJAGG60E1grc8HGWSrTd9kXw/640?wx_fmt=gif&amp;from=appmsg" data-type="gif" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXmIH3xGbloEopsHBwr4D3Ks7Qn46CSnBJAGG60E1grc8HGWSrTd9kXw/640?wx_fmt=gif&amp;from=appmsg"></section></section><section><section><p><strong><span leaf="">点个喜欢吧</span></strong></p></section></section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011077" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXzMxgcdhrYMf7gGzIHcPjXMLmAEBqhD2hvZwGcuCeBRUznRDZd1bCicw/640?wx_fmt=gif&amp;from=appmsg" data-type="gif" src="https://mmbiz.qpic.cn/sz_mmbiz_gif/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXzMxgcdhrYMf7gGzIHcPjXMLmAEBqhD2hvZwGcuCeBRUznRDZd1bCicw/640?wx_fmt=gif&amp;from=appmsg"></section></section><section><section><p><strong><span leaf="">分享让更多人看看</span></strong></p></section></section><section><section><section><section><svg viewbox="0 0 1 1"></svg></section></section></section><section><section><section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011074" data-ratio="0.662" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXrcdpPxltTicCpeSY1jCeaUyUtoEHXcAIeqcIgwG3VTgkicZ9ibicCymOCQ/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="500" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXrcdpPxltTicCpeSY1jCeaUyUtoEHXcAIeqcIgwG3VTgkicZ9ibicCymOCQ/640?wx_fmt=png&amp;from=appmsg"></section></section></section></section></section><section><section><section><svg viewbox="0 0 1 1"></svg></section></section></section></section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011076" data-ratio="0.4407407" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXjrrv8DNTAkz2NxaG8BR33Os23Fd7msZJe9UG5oQwic9iap6rXodOOVdA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXjrrv8DNTAkz2NxaG8BR33Os23Fd7msZJe9UG5oQwic9iap6rXodOOVdA/640?wx_fmt=png&amp;from=appmsg"></section></section><section><p><strong><span leaf="">设置</span><span><span leaf="">星标</span></span><span leaf="">，不错过精彩推文</span></strong></p></section><section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011082" data-ratio="0.3611111" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXywtia1YYsqQzh5LCuoBzltPTV0XIWHgicvFmOWfyh3OEnXsl10OMyICA/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="1080" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXywtia1YYsqQzh5LCuoBzltPTV0XIWHgicvFmOWfyh3OEnXsl10OMyICA/640?wx_fmt=png&amp;from=appmsg"></section></section><section><section><section><p><span><span leaf="">我知道你</span><span><strong><span leaf="">在看</span></strong></span><span leaf="">哟</span></span></p></section><section nodeleaf=""><img data-aistatus="1" data-imgfileid="100011083" data-ratio="0.9437939" data-s="300,640" data-src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXAsuOBbDbw1gJu3XyS6B7kv3SFOKXaTs5mB4Jp1kJfHVIII5dIrrSyg/640?wx_fmt=png&amp;from=appmsg" data-type="png" data-w="427" src="https://mmbiz.qpic.cn/sz_mmbiz_png/xpxHIze2P9mTBiaTn0SHFgBbiaibPovSALXAsuOBbDbw1gJu3XyS6B7kv3SFOKXaTs5mB4Jp1kJfHVIII5dIrrSyg/640?wx_fmt=png&amp;from=appmsg"></section></section></section></section><section><span leaf=""><br></span></section><p><mp-style-type data-value="3"></mp-style-type></p></div>  
<hr>
<a href="https://mp.weixin.qq.com/s/_uagHLRQjCK_ebtiDpeNTw",target="_blank" rel="noopener noreferrer">原文链接</a>
